Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors

Molecular Neurobiology

Volumn 53, Issue 4, 2016, Pages 2312-2319

  Aymerich, María S ^a,b,c   Rojo Bustamante, Estefanía ^a   Molina, Carmen ^b   Celorrio, Marta ^b   Sánchez Arias, Juan A ^b   Franco, Rafael ^b,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Recinto de Complejo Hospitalario de Navarra   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

2 AG; Cannabinoid receptor; Endocannabinoid; JZL184; Monoacylglycerol lipase; Neuroprotection

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 1 METHYL 4 PHENYLPYRIDINIUM; 1 METHYL 4 PHENYLPYRIDINIUM IODIDE; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACYLGLYCEROL LIPASE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; RIMONABANT; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; AMIDASE; ENZYME INHIBITOR; FATTY-ACID AMIDE HYDROLASE; NEUROPROTECTIVE AGENT; NEUROTOXIN; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEUROPROTECTION; NONHUMAN; SH SY5Y CELL LINE; ANTAGONISTS AND INHIBITORS; METABOLISM; TUMOR CELL LINE;

1-METHYL-4-PHENYLPYRIDINIUM; AMIDOHYDROLASES; BENZODIOXOLES; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; MONOACYLGLYCEROL LIPASES; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PIPERIDINES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84929440881     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9213-3     Document Type: Article

References (46)

1. Mechoulam R, Parker LA (2013) The endocannabinoid system and the brain. Annu Rev Psychol 64:21–47. doi:10.1146/annurev-psych-113011-143739
2. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50(1):83–90
3. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090):1946–1949
4. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284):561–564. doi:10.1038/346561a0
5. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441):61–65. doi:10.1038/365061a0
6. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99(16):10819–10824. doi:10.1073/pnas.152334899
7. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384(6604):83–87. doi:10.1038/384083a0
8. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87(5):1932–1936
9. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N et al (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16(4):411–420. doi:10.1016/j.chembiol.2009.02.013
10. Petrosino S, Di Marzo V (2010) FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11(1):51–62
11. Fernandez-Suarez D, Celorrio M, Riezu-Boj JI, Ugarte A, Pacheco R, Gonzalez H, Oyarzabal J, Hillard CJ et al (2014) The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2014.05.021
12. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153(2):240–251. doi:10.1038/sj.bjp.0707584
13. Onaivi ES (2006) Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54(4):231–246. doi:10.1159/000100778
14. Garcia MC, Cinquina V, Palomo-Garo C, Rabano A, Fernandez-Ruiz J (2015) Identification of CB(2) receptors in human nigral neurons that degenerate in Parkinson’s disease. Neurosci Lett 587:1–4. doi:10.1016/j.neulet.2014.12.003
15. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol Dis 19(1–2):96–107. doi:10.1016/j.nbd.2004.11.009
16. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, Strong R, Lutz B et al (2009) WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Eur J Neurosci 29(11):2177–2186. doi:10.1111/j.1460-9568.2009.06764.x
17. +-induced apoptosis in human SH-SY5Y neuroblastoma cells. J Neurosci Res 55(5):620–628. doi:10.1002/(SICI)1097-4547(19990301)55:5<620::AID-JNR9>3.0.CO;2-S
18. Pasquariello N, Catanzaro G, Marzano V, Amadio D, Barcaroli D, Oddi S, Federici G, Urbani A et al (2009) Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. J Biol Chem 284(43):29413–29426. doi:10.1074/jbc.M109.044412
19. Hynes J, Floyd S, Soini AE, O’Connor R, Papkovsky DB (2003) Fluorescence-based cell viability screening assays using water-soluble oxygen probes. J Biomol Screen 8(3):264–272. doi:10.1177/1087057103008003004
20. Yang MC, Chen KP, Lung FW (2014) Generalized estimating equation model and long-term exposure effect of antipsychotics on SH-SY5Y cells against oxidative stressors. Eur J Pharmacol. doi:10.1016/j.ejphar.2014.06.007
21. +-induced cell death. J Neurochem 125(3):473–485. doi:10.1111/jnc.12117
22. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM et al (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5(1):37–44. doi:10.1038/nchembio.129
23. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, Tontini A, Piersanti G et al (2004) Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 47(21):4998–5008. doi:10.1021/jm031140x
24. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38(11 Pt 1):3751–3757
25. Farooqui SM (1994) Induction of adenylate cyclase sensitive dopamine D2-receptors in retinoic acid induced differentiated human neuroblastoma SHSY-5Y cells. Life Sci 55(24):1887–1893
26. Buck KJ, Amara SG (1994) Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc Natl Acad Sci U S A 91(26):12584–12588
27. Kallendrusch S, Hobusch C, Ehrlich A, Nowicki M, Ziebell S, Bechmann I, Geisslinger G, Koch M et al (2012) Intrinsic up-regulation of 2-AG favors an area specific neuronal survival in different in vitro models of neuronal damage. PLoS ONE 7(12):e51208. doi:10.1371/journal.pone.0051208
28. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK et al (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334(6057):809–813. doi:10.1126/science.1209200
29. Nader J, Rapino C, Gennequin B, Chavant F, Francheteau M, Makriyannis A, Duranti A, Maccarrone M et al (2014) Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB receptors. Neuropharmacology. doi:10.1016/j.neuropharm.2014.03.014
30. Giordano M, Takashima H, Herranz A, Poltorak M, Geller HM, Marone M, Freed WJ (1993) Immortalized GABAergic cell lines derived from rat striatum using a temperature-sensitive allele of the SV40 large T antigen. Exp Neurol 124(2):395–400
31. Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti FA, Allara M, Sagredo O, Di Marzo V et al (2013) The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death Dis 4:e862. doi:10.1038/cddis.2013.387
32. Klegeris A, Bissonnette CJ, McGeer PL (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139(4):775–786. doi:10.1038/sj.bjp.0705304
33. Garcia C, Palomo-Garo C, Garcia-Arencibia M, Ramos J, Pertwee R, Fernandez-Ruiz J (2011) Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson’s disease. Br J Pharmacol 163(7):1495–1506. doi:10.1111/j.1476-5381.2011.01278.x
34. Gomez-Galvez Y, Palomo-Garo C, Fernandez-Ruiz J, Garcia C (2015) Potential of the cannabinoid CB receptor as a pharmacological target against inflammation in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. doi:10.1016/j.pnpbp.2015.03.017
35. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005) Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135(1):235–245. doi:10.1016/j.neuroscience.2005.06.009
36. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, Perchuk A, Mora Z et al (2008) Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS ONE 3(2):e1640. doi:10.1371/journal.pone.0001640
37. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL et al (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320(1):1–13. doi:10.1124/jpet.106.104463
38. Benard G, Massa F, Puente N, Lourenco J, Bellocchio L, Soria-Gomez E, Matias I, Delamarre A et al (2012) Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat Neurosci 15(4):558–564. doi:10.1038/nn.3053
39. Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, Mechoulam R, Benito C, Romero J et al (2008) The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 283(19):13320–13329. doi:10.1074/jbc.M707960200
40. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C et al (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 132(Pt 11):3152–3164. doi:10.1093/brain/awp239
41. Castillo A, Tolon MR, Fernandez-Ruiz J, Romero J, Martinez-Orgado J (2010) The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 37(2):434–440. doi:10.1016/j.nbd.2009.10.023
42. Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, Ledent C, Zimmer A et al (2010) Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 24(3):788–798. doi:10.1096/fj.09-141275
43. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML (2005) Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25(8):1904–1913. doi:10.1523/JNEUROSCI.4540-04.2005
44. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95(2):437–445. doi:10.1111/j.1471-4159.2005.03380.x
45. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T, Watanabe M, Guaza C et al (2009) The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis 33(1):57–71. doi:10.1016/j.nbd.2008.09.015
46. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57(5):1045–1050